This treatment is commonly used in situations involving a severe deficiency of both Luteinising Hormone (LH) and Follicle-Stimulating Hormone (FSH) in adult women.

Targeting Profound Central Hormone Deficiency

This therapeutic approach is generally used in women diagnosed with Hypogonadotropic Hypogonadism (HH), which is characterized by the absence of normal hormonal signaling necessary for reproduction. Luveris provides the essential LH activity that is missing, and this replacement may assist with the management of the underlying endocrine condition. The key clinical scenarios relevant for easing symptoms are severe LH deficiency and resulting anovulatory infertility.

Supporting Follicle Maturation and Ovulation

Luveris contributes to the therapeutic benefit by supporting the process of follicular development. Used concurrently with FSH as part of Controlled Ovarian Stimulation (COS), it plays a role in managing the growth and maturation of ovarian follicles. This targeted support helps to manage the clinical pattern of anovulatory infertility by enabling the ovaries to prepare structures capable of releasing an egg. The overall benefit supports the ability to achieve a goal of induced ovulation.

---

Quick Fact: Relief for Anovulatory Infertility

The medication is commonly used in fertility medicine and reproductive endocrinology to address the symptoms related to systemic imbalance that prevent normal follicular maturation and egg release.

Eligibility Map: Who Can and Cannot Use Luveris — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed: Adult women with severe Luteinising Hormone (LH) and Follicle-Stimulating Hormone (FSH) deficiency, often characterized by an endogenous serum LH level less than 1.2 IU/l.

Populations for whom use is contraindicated: Use is strictly prohibited in patients with hypersensitivity to gonadotrophins, specific cancers (ovarian, uterine, mammary carcinoma), or tumours of the hypothalamus and pituitary gland. Contraindications also include primary ovarian failure, unexplained gynaecological haemorrhages, and pre-existing physical conditions that render normal pregnancy impossible.

Age-related eligibility rules

Use is restricted to adult women. Safety and effectiveness have not been established in the pediatric or elderly populations, or in patients with renal or hepatic impairment.

Pregnancy and lactation eligibility status

Use is contraindicated during pregnancy and not indicated during lactation.

Eligibility-related restrictions

Patients must be evaluated and receive appropriate specific treatment for conditions such as hypothyroidism, adrenocortical deficiency, or hyperprolactinemia prior to starting Luveris. Caution is required for patients with a history of porphyria or recognised risk factors for thromboembolic events.

---

Connection to the overall eligibility profile

Regulatory documents define eligibility based on the presence of a specific central hormonal deficiency in adult women. The profile enforces rigorous exclusions for oncological and anatomical contraindications, and mandates conditional use where other endocrine disorders are present. It formally restricts use in populations lacking safety data, such as those with organ impairment or extreme age.

Interaction Scope

The official regulatory documentation for Lutropin Alfa is characterized by a high degree of specificity regarding the lack of general interaction data. Formal studies investigating drug–drug, drug–food, or drug–substance interactions, including those mediated by metabolic pathways like CYP enzymes, have not been performed according to the prescribing information.

Category	Official Regulatory Documentation Finding
Medicinal product categories with documented interactions	Only the gonadotropin Follitropin Alfa is addressed regarding co-administration.
Mechanistic basis of interactions (only if stated in label)	None documented. Formal studies for metabolic or transporter-based interactions are not available.
Interaction-related restrictions	Admixture Restriction: Must not be administered as a mixture in the same injection with any medicinal product other than Follitropin Alfa.

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation Finding
Interaction severity classification (as defined in official documents)	None listed. No specific drug-drug combinations are formally classified as contraindicated due to interaction risk.
Regulatory basis	Based on the EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Resulting Interaction Structure

Official Interaction Statements:

• The official regulatory documentation explicitly states that no general interaction studies have been performed for Lutropin Alfa with medicinal products other than Follitropin Alfa.
• Co-administration with Follitropin Alfa has been studied and found not to significantly alter the activity, stability, pharmacokinetic, or pharmacodynamic properties of either active substance.

The regulatory documentation defines the interaction structure primarily by the absence of general interaction data, indicating that official information on pharmacokinetic, metabolic, or transporter-based interactions is unavailable. The profile's central constraint is a mandatory admixture restriction, prohibiting the physical mixing of Lutropin Alfa with any substance other than Follitropin Alfa in the same injection device.

How Luveris Works

Lutropin Alfa acts as an agonist for Luteinising Hormone (LH) receptors, directly activating the biological pathways that initiate ovarian hormone production.

Specific Receptor Activation and Steroidogenesis Initiation

Lutropin Alfa acts as a high-affinity agonist for the Luteinising Hormone/Choriogonadotropin Receptor (LHCGR), which is located primarily on ovarian theca cells. This targeted binding triggers an intracellular signaling cascade, specifically the cAMP pathway, which ultimately activates steroidogenic enzymes. This molecular interaction initiates the physiological production and secretion of androgen precursors (molecular substrate) into the follicular environment.

Synergy within the Two-Gonadotropin Pathway

Lutropin Alfa's mechanism operates within the Two-Cell, Two-Gonadotropin system, requiring cooperation with Follitropin Alfa (FSH activity). While Lutropin Alfa supplies the necessary androgen substrate, FSH activity simultaneously prepares adjacent granulosa cells by upregulating the aromatase enzyme. This critical synergy allows the granulosa cells to convert the androgens into high levels of Estradiol (E2). The resulting increase in E2 acts as the systemic hormonal signal that supports the final proliferation and maturation of the ovarian structure.

Official Administration Guidelines for Luveris

Luveris (lutropin alfa) is administered through subcutaneous injection (under the skin) as a component of a fertility treatment regimen. It is given as a course of daily injections administered simultaneously with a Follicle-Stimulating Hormone (FSH) preparation, such as follitropin alfa.

Dosing and Preparation

The starting regimen involves one vial of Luveris (75 IU of lutropin alfa) daily, administered along with 75 IU to 150 IU of FSH. The final dose of FSH is individually tailored by a physician based on the patient's response, monitored through ultrasound and estrogen levels. The treatment duration can be extended up to five weeks, if necessary, and subsequent dose adjustments should occur at 7 to 14-day intervals.

Luveris is a lyophilized powder that must be reconstituted immediately prior to use using the solvent provided. The reconstituted solution must be clear and colorless. It should be swirled gently—not shaken—until the powder is dissolved. The reconstituted Luveris may be mixed with the concomitant FSH preparation (e.g., follitropin alfa) and given as a single injection.

Administration Procedure

Patients should receive training for self-administration, but the first injection must be performed under direct medical supervision. The injection site should be alternated daily. If a daily dose is missed, the patient must immediately contact their physician or nurse for advice; a double dose should not be taken to compensate for a forgotten dose. The treatment is initiated in adult women with specific hormonal deficiencies and must be conducted under the supervision of a physician experienced in fertility treatment. Once an optimal follicular response is achieved, a dose of human chorionic gonadotropin (hCG) is administered 24 to 48 hours after the final Luveris and FSH injections to trigger final egg maturation.

Research Evidence: Overview of Studies for Lutropin Alfa

Evidence for use in Follicular Development in Profound Hormone Deficiency

Research has examined the use of lutropin alfa, in combination with recombinant FSH, in women diagnosed with a profound deficiency of both Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). Conditions characterized by functional limitations due to hormonal imbalance were evaluated in these research settings. The studies conducted were primarily short-term randomized comparative studies. These trials were used in research exploring how symptoms change over time and studies monitored physiological outcomes, such as the growth and maturation of ovarian follicles.

Research describes patterns observed in the studies where the use of lutropin alfa was explored in the treatment plan. Research highlights changes measured during the study period, where patterns were observed related to follicle maturation and ovulation in the study groups. These findings describe patterns observed in the studies conducted over defined time intervals, providing insight into short-term changes in the growth of ovarian follicles.

However, follow-up durations were limited in the initial trials, meaning long-term effects are not fully established regarding outcomes beyond the treatment cycle. Furthermore, the results apply only to the populations studied, which were highly selected based on specific diagnostic criteria for profound deficiency. Comparative evidence is lacking against all potential alternative approaches.

Evidence in Other Female Infertility Treatment Settings

Lutropin alfa was evaluated in research settings beyond the primary indication, primarily in randomized trials exploring its use as a supplement during standard ovarian stimulation protocols for women undergoing assisted reproductive techniques (ART). These studies were interested in outcomes related to systemic or functional imbalance, such as the number of eggs retrieved and characteristics of the embryos developed.

Findings were mixed across studies regarding whether the use of lutropin alfa in these broader groups was associated with patterns different from standard protocols without the added medication. Evidence quality varies across studies, and research provides context but not individual predictions regarding success rates in these settings.

What is Still Uncertain about Lutropin Alfa

The majority of the research highlights changes measured during the study period only up to the point of embryo transfer or when a pregnancy was established. Certainty remains low regarding the durability of the treatment's reported patterns and the long-term health outcomes for both mother and child. Subgroup findings are uncertain when applied to older women or those with certain medical conditions, as the data for certain groups remain insufficient in the existing trials. Researchers continue to explore these areas to contribute to the broader evidence landscape.

Key Studies & References

1. Lutropin alfa: a guide to its use in female infertility

Common questions about Luveris (FAQ)

Q: Does Luveris cause headaches or dizziness?

The official safety profile lists headache as a common side effect, meaning it has been reported in 1% to 10% of patients during clinical trials. Although less frequently reported, dizziness is also described in the regulatory literature. In general, it is advisable that any unexpected or severe symptoms are discussed with the treating physician or nurse.

Q: What are the most commonly reported injection site reactions with Luveris?

Injection site reactions are commonly reported adverse events. The types of reactions described in regulatory documents include local symptoms such as pain, redness, swelling, bruising, and itching at the injection site.

Q: Can Luveris affect my ability to drive or operate machinery?

The official product information includes a section discussing the potential effects on the ability to drive and use machines. The official documentation does not list general restrictions on driving or operating machinery, but any concerns related to specific side effects should be assessed by a physician.

Q: Is it common for people to experience breast tenderness while taking Luveris?

Yes, breast pain is classified in official safety documents as a common adverse reaction, meaning it may affect between 1% and 10% of patients. This adverse event is officially classified as breast pain, which is commonly described as tenderness.

Q: What has research shown about Luveris and the risk of ovarian hyperstimulation syndrome (OHSS)?

Ovarian hyperstimulation syndrome (OHSS) is identified in the official safety profile as a serious risk tied to this type of treatment. Regulatory documents describe that OHSS was observed in less than 6% of patients treated with Luveris in clinical trials. Careful monitoring is described in regulatory documents as an essential component of the treatment protocol intended to minimize this risk.

Q: What are the official recommendations about what to do if I feel faint after the injection?

Official regulatory documents do not provide specific instruction for general faintness, but they emphasize that any unexpected or concerning symptoms should be discussed with a physician. They also advise immediately consulting a healthcare professional if a dose is missed.

Q: Is the medication intended for multiple cycles or only a single one?

Luveris is administered as a course of daily injections, typically used in one treatment course that may last up to five weeks. Regulatory documents confirm that treatment cycles can be stopped and potentially recommenced in a subsequent cycle, though the decision to use the medication in subsequent cycles is based on clinical assessment.

Q: Does Luveris have a potential to cause mood swings?

Regulatory documents note that psychiatric reactions such as anxiety, depression, and nervousness have been reported during treatment. However, the frequency of these psychiatric reactions is not commonly reported or quantified in the official safety profile.

Q: Has Luveris been studied in women over the age of 40?

The official documentation states that Luveris use is restricted to adult women. Regulatory documents also state that data for certain groups, including older women, remain insufficient in the existing trials, and certainty remains low for subgroup findings.

Q: Why is Luveris described as a recombinant human luteinizing hormone?

Luveris is described this way because the active ingredient, Lutropin Alfa, is a highly purified hormone. It is manufactured using advanced recombinant DNA technology within genetically modified cells to ensure a consistent and high-quality preparation.

Q: Does Luveris work the same way for all women?

While the hormone's mechanism of action is consistent, the response varies, requiring the final dose to be individually tailored by a physician. Official research documents state that the study results apply only to the highly selected populations that were included in the trials.

Q: What types of interactions are described for Luveris with herbal supplements?

Official regulatory documentation explicitly states that formal studies investigating drug–drug, drug–food, or drug–substance interactions, which includes herbal supplements, have not been performed for Lutropin Alfa.

Q: What official documents say about Luveris and multiple births?

The official warnings and precautions section of the regulatory documents addresses this. It states that the incidence of multiple pregnancies and births is increased in patients undergoing this type of treatment compared with natural conception.

Q: Are there any food or diet restrictions described for people using Luveris?

Official regulatory documentation explicitly states that formal interaction studies for drug–food or drug–substance interactions have not been performed. Official guidance indicates that a physician's instructions should be followed regarding any restrictions related to diet or food intake.

Q: Is Luveris known to interact with common pain relievers like ibuprofen?

The official interaction documentation is highly specific, stating that no general interaction studies have been performed for Lutropin Alfa with medicinal products other than the necessary co-administered Follitropin Alfa.

Q: How does the official literature describe the expected results from using Luveris?

The official research literature describes the physiological outcomes that were measured in studies. These include patterns observed related to the growth and maturation of ovarian follicles and the process of ovulation in the study groups.

Q: Are there any restrictions on physical activity while using Luveris?

Official regulatory documents advise following a physician's instructions regarding any restrictions on activity. Official regulatory documents advise following a physician's instructions regarding any restrictions on activity.

Q: Is Luveris only for women, or is it used in men for any condition?

The official eligibility map restricts the use of this medicine to adult women. Its authorized use is specifically for the stimulation of follicular development in cases of severe Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) deficiency.

Q: Does Luveris have an effect on weight gain or loss?

Weight change itself is not listed as a common side effect. However, rapid weight gain is specifically cited in regulatory documents as an early warning sign of the serious adverse reaction known as Ovarian Hyperstimulation Syndrome (OHSS).

Q: What is the difference between Luveris and menotropins containing hCG?

The active ingredient in Luveris is recombinant human Luteinizing Hormone (r-hLH), which provides a high-purity source of LH activity. In contrast, some menotropin preparations have LH activity augmented by containing human chorionic gonadotropin (hCG), which has similar but not identical effects.

Q: Are there specific safety warnings related to Luveris and blood clotting issues?

Yes, regulatory documents describe Thromboembolic Events (blood clots) as a very rare risk. Furthermore, they warn that the risk may be further increased in women who have recognized risk factors for blood clotting issues.

Q: Can Luveris be used by people with polycystic ovary syndrome (PCOS)?

The official eligibility documents address this by stating that use is strictly contraindicated for ovarian enlargement or cysts that are unrelated to polycystic ovarian disease. This distinction describes the parameters for use, based on the presence or absence of PCOS.

Q: Does Luveris affect vision or eye health?

Problems with vision are mentioned in the regulatory documents as a sign of a potential serious event, such as a blood clot, which would necessitate consulting a healthcare professional. Additionally, minor effects like conjunctivitis have been reported, though their frequency is not commonly known.

Q: Are there different forms or doses of Luveris available?

Luveris is supplied as a lyophilized powder and a solvent that are mixed together to create a solution for injection. The approved product is typically in a 75 IU (one vial) dosage.

Q: What does the official information say about Luveris and long-term ovarian health?

The official research overview states that follow-up durations were limited in the initial clinical trials. This means that long-term effects regarding ovarian health and outcomes beyond the specific treatment cycle are not fully established.

Q: Can I use Luveris if I have diabetes?

Diabetes is cited in regulatory documents as a recognized risk factor for certain underlying conditions, such as coronary artery disease. These conditions may increase the risk of serious side effects like thromboembolic events.

Q: What is the difference between Luveris and other menotropin preparations?

Luveris is the first and only recombinant human form of Luteinising Hormone (r-hLH). This production method provides high purity, which is the primary factor differentiating it from older, urinary-derived gonadotropin preparations.

Q: What are the known components of Luveris besides the active ingredient?

The composition includes the active ingredient, Lutropin Alfa, and several excipients. These excipients, such as sucrose and sodium phosphate salts, are necessary to ensure the stability of the recombinant hormone preparation.

Storage and Disposal Instructions

Unreconstituted Vials: The Luveris powder and solvent vials must be stored in the original package to protect from light. Storage temperature must not be above 25 C (77 F), and the product must not be frozen. The vials may be stored at a refrigerated temperature of 2 C to 8 C as an alternative.

Reconstituted Solution: The mixed solution is for immediate and single use only and must be administered right after preparation. Do not use the solution if it contains particles.

Child Safety: This medicine must be kept out of the sight and reach of children.

Disposal: Any unused product, waste material, and the unused solution must be discarded according to local requirements. Medicines should not be thrown away via household waste or wastewater. Used needles and glass components must be placed immediately into a sharps container.